40252-11-7Relevant articles and documents
The β-glucuronyl-based prodrug strategy allows for its application on β-glucuronyl-platinum conjugates
Tromp, Reynier A.,Van Boom, Stella S.G.E.,Timmers, C. Marco,Van Zutphen, Steven,Van Der Marel, Gijsbert A.,Overkleeft, Herman S.,Van Boom, Jacques H.,Reedijk, Jan
, p. 4273 - 4276 (2004)
The use of platinum drugs in antitumour therapy is well established. An important drawback of these chemotherapeutics is the lack of selectivity for tumour cells, usually resulting in severe toxic side effects. A glucuronyl-platinum conjugate was designed and synthesised to test the compatibility of platinum compounds with β-glucuronidase-based prodrug therapy. Instantaneous cleavage of the β-glucuronic bond in the glucuronyl-platinum conjugate was observed upon addition of β-glucuronidase resulting in PtII(dach)(4-hydroxybenzylmalonate) and glucuronic acid.
Reactions of difluorocarbene with organozinc reagents
Levin, Vitalij V.,Zemtsov, Artem A.,Struchkova, Marina I.,Dilman, Alexander D.
, p. 917 - 919 (2013/03/28)
Reactions of difluorocarbene with benzyl and alkylzinc halides leading to fluorinated organozinc species have been described. The generated α-difluorinated organozinc reagents are reasonably stable in solution and can be quenched with external electrophiles (iodine, bromine, proton), affording compounds containing the CF2 fragment.
Antiosteoporotic imidazo[4,5-c]pyridines
-
, (2008/06/13)
This invention relates to 2-substituted-imidazo[4,5 -c]pyridines, to the process for their preparation, to pharmaceutical compositions containing said 2-substituted-imidazo]4,5-c]pyridines and to the use of said 2-substituted-imidazo[4,5-c]pyridines for modifying the balance between bone production and bone resorption in a host animal, including man.
